Bausch Health

44 articles about Bausch Health

• New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis

  5/18/2023

  Bausch Health Companies Inc. today announced the publication of a new study, which showed that ARESTIN (minocycline HCI) microspheres, 1mg decreased certain pathogenic burdens, also known as infection burdens, in adults with periodontitis when applied immediately after scaling and root planning (SRP) and again at a three-month reapplication, versus SRP alone.

• Bausch Health Announces 2023 Annual Meeting of Shareholder Results

  5/17/2023

  Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the results of its 2023 annual meeting of shareholders.

• Bausch Health Observes Mental Health Awareness Month

  5/10/2023

  Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is proud to recognize May as Mental Health Awareness Month by continuing efforts that highlight the importance of educating and supporting those with mental health care needs.

• Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023

  5/8/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today will deliver a podium presentation of its research titled "Impact of Rifaximin Use During The 30-Day Post-Discharge Period Following an Overt Hepatic Encephalopathy Hospitalization on Healthcare Utilization And Costs" during Digestive Disease Week® (DDW) 2023, which will be held virtually and in-person in Chicago, IL through Tuesday, May 9, 2023.

• Public advisory - Bausch Health, Canada Inc. recalls all lots of Emerade epinephrine auto-injectors (0.3 mg and 0.5 mg strengths) due to possible device failure

  5/5/2023

  Emerade epinephrine auto-injectors, 0.3 mg (DIN 02458446) and 0.5 mg (DIN 02458454) Issue: Health products – Mechanical defect What to do: Return your Emerade auto-injector to your pharmacy for a suitable replacement as soon as possible.

• Bausch Health Announces First-Quarter 2023 Results

  5/4/2023

  Bausch Health Companies Inc. today announced its first-quarter 2023 financial results.

• Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel

  5/1/2023

  Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for investigational IDP-126 (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) Gel with a Prescription Drug User Fee Act (PDUFA) action date of October 20, 2023.

• Salix Partners with the Colorectal Cancer Alliance on Community Screening Program

  4/24/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced a partnership with the Colorectal Cancer Alliance, the nation's nonprofit leader dedicated to combatting colorectal cancer, to increase awareness and access to preventative colorectal screenings in medically underserved communities.

• Bausch Health to Announce First-Quarter 2023 Results on May 4

  4/13/2023

  Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its first-quarter financial results on Thursday, May 4, 2023.

• New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider

  4/4/2023

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals, announced the results from the third edition of its patient perspectives survey, an annual survey of U.S. adults living with irritable bowel syndrome or chronic idiopathic constipation.

• Bausch Health Announces Changes to its Board of Directors

  3/1/2023

  Bausch Health Companies Inc. (TSX:BHC)(NYSE:BHC) today announced that Richard De Schutter and Dr. Argeris Karabelas are retiring from the Company's Board of Directors, effective as of the upcoming 2023 annual meeting of shareholders of the Company.

• Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results

  2/23/2023

  Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced its fourth-quarter and full-year 2022 financial results.

• Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23

  2/1/2023

  Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2022.

• First tazarotene lotion treatment for acne vulgaris, ARAZLO TM (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans

  12/22/2022

  Bausch Health Companies Inc. today announced that its new topical prescription treatment for acne vulgaris, ARAZLO TM  (tazarotene lotion, 0.045% w/w), is now available to patients.

• Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference

  11/1/2022

  Bausch Health Companies Inc. today announced the presentation of nine posters during the Innovations in Dermatology Conference, which takes place Nov. 3-5, 2022, in Las Vegas, Nev.

• Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge

  10/31/2022

  Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, recently announced the launch of the Podiatry Board Review Challenge, a new professional educational resource.

• Salix Will Present XIFAXAN(R) (Rifaximin), TRULANCE(R) (Plecanatide) and RELISTOR(R) (Methylnaltrexone Bromide) Data at The American College of Gastroenterology(R) 2022 Annual Scientific Meeting

  10/24/2022

  Bausch Health Companies Inc. and its gastroenterology business, Salix Pharmaceuticals today announced four posters and one abstract featuring data for XIFAXAN (rifaximin), TRULANCE (plecanatide) and RELISTOR (methylnaltrexone bromide) that are being presented at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.

• Ortho Dermatologics To Present New Data at the 2022 Fall Clinical Dermatology Conference

  10/20/2022

  Bausch Health Companies Inc. today announced the presentation of eleven posters during the Fall Clinical Dermatology Conference, which takes place Oct. 20-23, 2022 in Las Vegas, Nev.

• Bausch Health to Announce Third Quarter 2022 Results on Nov. 3

  10/13/2022

  Bausch Health Companies Inc. will release its third quarter financial results on Thursday, Nov. 3, 2022.

• Seasonal Affective Disorder (SAD) Is Now a Recognized Diagnosis in the CMS Tabular Index, Accessible to Prescribers Oct. 1, 2022

  10/5/2022

  Bausch Health Companies Inc. is continuing its commitment to improving lives with the announcement of modifications within the Tabular Index, specifically for the prevention and treatment of SAD from the Centers for Medicare & Medicaid Services.